Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NORTHWEST BIOTHERAPEUTICS INCNWBO · Entity 5982 | Director | December 01, 2022 | December 06, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NORTHWEST BIOTHERAPEUTICS INC
Report date December 01, 2022 · Filed December 06, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Series C Convertible Preferred StockSEC Table I · non-derivative | Direct | 28,235 |
Reported balance
After 2022-12-01 transaction · row 1
1 source rowRow 1 · 2022-12-01 · Grant · Acquired 28,235 · Balance 28,235 F1: On December 1, 2022, the Issuer and Mr. Jasinowski entered into a Subscription Agreement (the "Agreement"). Pursuant to the Agreement, Mr. Jasinowski purchased 28,235 shares of the Issuer's Series C Convertible Preferred Stock at a price per share of $21.25, for an aggregate purchase price of approximately $600,000. |
Filing footnotes · ownership attribution and instrument terms
F1: On December 1, 2022, the Issuer and Mr. Jasinowski entered into a Subscription Agreement (the "Agreement"). Pursuant to the Agreement, Mr. Jasinowski purchased 28,235 shares of the Issuer's Series C Convertible Preferred Stock at a price per share of $21.25, for an aggregate purchase price of approximately $600,000.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 01, 2022 Filed Dec 6, 2022 01:56 UTC | NORTHWEST BIOTHERAPEUTICS INC NWBO · Entity 5982 | GrantSeries C Convertible Preferred Stock | 28,235 | $21.25 | $599,993.75 |
DisclosureSEC source: 0001104659-22-124667 · tm2231996-1_4seq1.xml · nonDerivative · entry 1 JASINOWSKI JERRY J · CIK 0001204048 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,235 F1 · kind: On December 1, 2022, the Issuer and Mr. Jasinowski entered into a Subscription Agreement (the "Agreement"). Pursuant to the Agreement, Mr. Jasinowski purchased 28,235 shares of the Issuer's Series C Convertible Preferred Stock at a price per share of $21.25, for an aggregate purchase price of approximately $600,000. Read SEC document |
| February 03, 2020 Filed Feb 6, 2020 02:45 UTC | NORTHWEST BIOTHERAPEUTICS INC NWBO · Entity 5982 | GrantCommon Stock | 526,316 | $0.19 | $100,000.04 |
DisclosureSEC source: 0001104659-20-011526 · tm206922-1_4.xml · nonDerivative · entry 1 JASINOWSKI JERRY J · CIK 0001204048 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,891,347 F1 · kind: On February 3, 2020, the Issuer and Mr. Jasinowski entered into a Stock Purchase Agreement (the "Agreement"). Pursuant to the Agreement, Mr. Jasinowski purchased 526,316 shares of the Issuer's Common Stock at a price per share of $0.19, for an aggregate purchase price of approximately $100,000. Read SEC document |
| May 28, 2018 Filed May 31, 2018 01:57 UTC | NORTHWEST BIOTHERAPEUTICS INC NWBO · Entity 5982 | GrantOptions to purchase Common Stock, par value $0.001 · Derivative | 4,900,000 | Not disclosed Strike: $0.23 | Not disclosed |
DisclosureSEC source: 0001144204-18-031797 · tv495289_4.xml · derivative · entry 1 JASINOWSKI JERRY J · CIK 0001204048 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,900,000 Underlying: Common Stock, par value $0.001 · 4,900,000 shares Expires 2028-05-28 F1 · shares: These 4,900,000 Options were previously reported and were approved by shareholders at the Special Shareholder Meeting on April 27, 2018. Half of the Options are vested at the time of issuance and half will vest monthly over the course of 24 months from the date of Board approval, subject to acceleration in certain circumstances. F2 · price: The exercise price of the Options is $0.23. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.